S S Korsakov Journal of Neurology and Psychiatry · 2019 · 11 citations · 3 references
PharmacyPharmacokineticsPharmacologyClinical ImmunologyClinical PharmacologyMonoclonal AntibodiesAntibody CharacterizationAntibody PharmacokineticsDiagnostic Monoclonal AntibodiesMonoclonal Antibody TherapyPharmacokinetics Of Monoclonal AntibodiesTherapeutic Monoclonal AntibodiesAdministration Of Monoclonal AntibodiesAnti-cd20 Antibody TherapyAnti-cd20 TherapyMonoclonal Antibodies In CancerMonoclonal Antibody CharacterizationMonoclonal Antibody InfusionMonoclonal Antibody Therapeutics
Boyko OV, Boyko AN, Yakovlev PA, Zinkina-Orikhan AV, Kotov SV, Lin’kova YuN, Prakhova LN, Totolyan NA, Shchur SG, Ivanov RA. Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety. S.S. Korsakov Journal of Neurology and Psychiatry.
3
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman, Stephen C. Reingold, Brenda Banwell et al. · Annals of Neurology · 2011 · 9.8K citations · Full text
Medicine, Neurology, Neuroscience +10
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Stephen L. Hauser, Amit Bar‐Or, Gavin Giovannoni et al. · New England Journal of Medicine · 2016 · 2K citations · Full text
Life Sciences, Immunology, Neurology +17
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Xavier Montalbán, Stephen L. Hauser, Ludwig Kappos et al. · New England Journal of Medicine · 2016 · 1.9K citations · Full text
Life Sciences, Immunology, Neurology +17